Trust Signals
Evidence standard: Claims graded by evidence type. Speculative claims labeled. No affiliate relationships influence scoring.
Regulatory status clearly stated: Tesamorelin (Egrifta SV) is FDA-approved for one indication only. Off-label and research use is addressed honestly.
Key Takeaways
- Branded Egrifta SV costs roughly $2,000, $3,500 per month at retail; compounded tesamorelin from a licensed 503A pharmacy costs approximately $150, $400 per month with a valid prescription.
- Tesamorelin reduced visceral adipose tissue by roughly 15 to 18% versus placebo in Phase III RCTs (n>800) in HIV-positive adults, making it the best-evidenced GHRH analog for visceral fat reduction.
- The peptide's N-terminal trans-3-hexenoic acid modification extends plasma half-life compared to native GHRH(1-44) by resisting DPP-IV cleavage; this structural change is the pharmacological basis for its once-daily dosing.
- Research-grade vials online range $30, $80 per 2 mg, but without independent COA verification, purity and identity are unconfirmed; molecular weight should be approximately 5135 Da.
- Evidence for tesamorelin in healthy, non-HIV adults is limited to smaller trials; off-label use cannot be given the same confidence rating as the approved HIV lipodystrophy indication.
What Does Tesamorelin Cost, and Is It Worth Buying?
Tesamorelin cost depends almost entirely on which form you access: branded Egrifta SV through a specialty pharmacy (expensive, insurance-dependent, narrow approved indication), compounded tesamorelin through a 503A pharmacy (moderately priced, requires prescription, quality varies by compounder), or research-grade vials sold online (lowest price, no regulatory quality guarantee, legally ambiguous for human use). The evidence for visceral fat reduction in its approved population is robust; evidence for off-label use in healthy adults is real but smaller in magnitude.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Tesamorelin cost and price breakdown by source
- What is tesamorelin? Mechanism with specific numbers
- Evidence ledger: what the data actually show
- What most pages get wrong about tesamorelin
- Storage and formulation chemistry: why the rules matter
- Honest head-to-head: tesamorelin vs alternatives
- How to read a COA and judge product quality
- Side effects, contraindications, and IGF-1 monitoring
- Legal and regulatory status: compounded vs research grade
- FAQ
- Sources
What Does Tesamorelin Cost and Where Can You Buy It?
Price is the first question for most buyers, so here is the transparent breakdown across three access pathways:
| Source | Approx. Monthly Cost | Regulatory Status | Quality Guarantee | Requires Rx? |
|---|---|---|---|---|
| Branded Egrifta SV (Theratechnologies) | $2,000, $3,500 before insurance/assistance | FDA-approved drug | FDA-regulated manufacturing (cGMP) | Yes |
| Compounded tesamorelin (503A pharmacy) | $150, $400 | Legal with valid Rx; not FDA-approved product | USP <797> sterile compounding standards; quality varies | Yes |
| Research-grade vials (online vendors) | $30, $80 per 2 mg vial (~$60, $160/month at standard dose) | Sold as "not for human use"; legally gray for human administration | No guarantee; COA may or may not exist | No |
Patient assistance programs from Theratechnologies can reduce or eliminate Egrifta SV costs for qualifying patients (HIV-positive adults meeting clinical criteria). Most private insurers cover Egrifta SV only for the FDA-approved indication. For off-label use, compounded tesamorelin at a licensed 503A pharmacy is the only pathway that combines reasonable cost with a regulated manufacturing framework.
What Is Tesamorelin? Mechanism With Specific Numbers
Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), which is a 44-amino-acid hypothalamic peptide. The drug retains the complete GHRH(1-44) sequence but adds a trans-3-hexenoic acid group at the N-terminal alpha-amino group. This single modification confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary degradation pathway for native GHRH in plasma.
Pharmacokinetic data from the Egrifta SV prescribing information show a mean terminal half-life of approximately 26 to 38 minutes after subcutaneous injection in HIV-positive adults, compared to native GHRH, which has a plasma half-life of only a few minutes. Peak plasma concentration (Cmax) occurs approximately 15 to 30 minutes post-injection. Despite the relatively short half-life by peptide-drug standards, the pulsatile GH response is sufficient to raise mean IGF-1 levels meaningfully; in the Phase III trials, IGF-1 increased to within or above normal age-adjusted ranges in the majority of treated patients.
The downstream pathway: GHRH receptor (GHRHR) activation on anterior pituitary somatotrophs increases intracellular cAMP via Gs protein coupling, triggering GH synthesis and release. Elevated GH acts on hepatic GH receptors to stimulate IGF-1 production. IGF-1 then activates lipolysis in visceral adipocytes through hormone-sensitive lipase and other mechanisms. The net result is preferential reduction of visceral (intra-abdominal) fat rather than subcutaneous fat, consistent with the higher density of GH receptors in visceral adipose tissue.
Evidence Ledger: What the Data Actually Show
| Claim | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| Reduces visceral fat in HIV lipodystrophy | 2 Phase III RCTs, n>800 (Falutz et al., 2007, 2010) | Positive: ~15 to 18% VAT reduction vs placebo at 26 weeks by CT | High | Effects partially reverse within weeks of stopping; population is HIV+ adults on ART |
| Raises IGF-1 levels | Phase III RCT data (prescribing information) | Positive: IGF-1 elevated into or above normal range | High | Elevated IGF-1 is a biomarker, not a proven surrogate for clinical outcomes |
| Reduces visceral fat in healthy/aging non-HIV adults | Smaller RCTs (Bhatt et al. 2018, Baker et al. 2012 context) | Positive but smaller effect size | Moderate | Sample sizes smaller; populations different; effect durability unclear |
| Improves cognitive function (aging adults) | RCT (Baker et al., Arch Neurol / JAMA Intern Med, ~2012) | Modest positive signal in verbal memory | Low-Moderate | Single trial, small n, mechanism not established; not replicated at scale |
| Improves muscle mass or strength | Secondary endpoints in HIV trials; no primary RCT in healthy adults | Weak/neutral | Low | Not a demonstrated primary effect; not an approved or supported claim |
| Anti-aging or longevity benefit | Mechanism/extrapolation only | Speculative | Very Low | No human RCT evidence; elevated IGF-1 has complex longevity biology |
What Most Pages Get Wrong About Tesamorelin
The single biggest error on commodity peptide pages is treating compounded or research-grade tesamorelin as pharmacologically equivalent to Egrifta SV simply because the amino-acid sequence matches. Here is what gets omitted:
1. The N-terminal modification is structurally fragile. The trans-3-hexenoic acid moiety at the N-terminus is the entire basis for DPP-IV resistance. Any oxidation, hydrolysis, or aggregation event that damages this modification reduces bioactivity without necessarily changing the product's appearance in a vial. A product that "looks fine" may have lost meaningful potency. Only mass spectrometry and HPLC purity data can confirm the modification is intact and the peptide is full-length and unaggregated.
2. Subcutaneous bioavailability is substantially less than 100% and is formulation-dependent. Like all peptide therapeutics administered subcutaneously, tesamorelin is subject to pre-systemic degradation at the injection site, lymphatic uptake variability, and protease exposure in interstitial fluid. The Egrifta SV prescribing information reports pharmacokinetic parameters from the approved formulation; research vials reconstituted in bacteriostatic water without optimized excipients may not replicate those pharmacokinetics. No independently published absolute bioavailability figure for this specific product should be assumed to apply to compounded or research-grade preparations.
3. The VAT reduction effect is population-specific. The 15 to 18% VAT reduction figure originates in people with HIV-associated lipodystrophy, a condition involving profoundly dysregulated fat distribution driven partly by antiretroviral therapy. Extrapolating this effect size to healthy adults with modestly elevated visceral fat is not scientifically justified. Smaller trials in non-HIV populations show a real but attenuated effect.
4. Rebound after stopping is not emphasized. In the Phase III extension data (Falutz et al. 2010), a significant proportion of VAT reduction was lost within 6 months of discontinuation. This is a chronic-use drug by its own trial design, not a course of treatment with lasting benefit. Cost calculations need to account for this.
Storage and Formulation Chemistry: Why the Rules Matter
Tesamorelin as a lyophilized (freeze-dried) powder should be stored at 2 to 8°C and protected from light. The reason is specific chemistry, not convention:
- Hydrolysis: Peptide bonds hydrolyze in aqueous solution; this is accelerated by elevated temperature (roughly a log-linear relationship per the Arrhenius equation). A vial left at room temperature for an extended period accumulates hydrolysis fragments that are pharmacologically inactive and potentially immunogenic. Lyophilization arrests this degradation by removing water.
- Oxidation of methionine: GHRH(1-44) contains a methionine residue at position 27. Methionine sulfoxide formation from oxidative exposure reduces receptor binding affinity. Light accelerates this reaction via photosensitized oxidation. This is why the prescribing information specifies light protection, not just temperature.
- Aggregation: Once reconstituted, peptide concentration, pH, and temperature all affect aggregation kinetics. Egrifta SV uses a proprietary formulation to reduce aggregation; research-vial reconstitution in bacteriostatic water at variable concentrations does not reproduce these conditions. Aggregated peptide has reduced bioactivity and higher immunogenicity risk.
- Freeze-thaw cycles: Each freeze-thaw cycle increases the probability of aggregation and crystal-induced fragmentation. Research vials that have been improperly shipped or stored cannot be visually assessed for this damage.
The rule: reconstitute only what you will use immediately. Never assume a previously reconstituted vial retains potency.
Honest Head-to-Head: Tesamorelin vs Alternatives
| Agent | Mechanism | Human RCT Evidence for VAT/Body Composition | Half-life | Where Tesamorelin Wins | Where Tesamorelin Loses |
|---|---|---|---|---|---|
| Tesamorelin | GHRH receptor agonist (pulsatile GH) | Phase III RCTs, n>800; FDA-approved | ~26 to 38 min (SC) | Strongest evidence base; approved drug status | Cost; requires refrigeration; rebound on cessation |
| Sermorelin | GHRH receptor agonist (truncated GHRH 1-29) | Small trials, pediatric GH deficiency; minimal adult body composition RCTs | ~10 to 12 min (SC) | Lower cost compounded; longer safety record in peds | Loses to tesamorelin on evidence quality and potency; shorter half-life |
| CJC-1295 (with DAC) | GHRH receptor agonist; DAC extends half-life via albumin binding | One small RCT (Teichman et al. 2006); no Phase III VAT data | Days (with DAC) | Less frequent dosing (weekly) | Loses badly on clinical evidence; DAC causes non-pulsatile GH elevation ("GH bleed"); unknown long-term safety |
| Ipamorelin / GHRP-2 | Ghrelin receptor agonist (GH secretagogue, different receptor) | Small phase I/II; no Phase III body composition RCTs | Minutes | Often combined with GHRH analogs; low cortisol/prolactin effect (ipamorelin) | No comparative RCT vs tesamorelin; different receptor class; weaker evidence |
| Recombinant hGH (somatropin) | Direct GH receptor agonist | Extensive RCT data in GH deficiency; some body composition data in aging | ~2 to 3 hours (SC) | More potent GH elevation; well-understood pharmacology | Suppresses endogenous GH axis; higher side-effect profile (edema, carpal tunnel, diabetes risk); controlled substance (Schedule III) |
How to Read a COA and Judge Tesamorelin Product Quality
When buying any tesamorelin peptide for sale from a compounding pharmacy or research vendor, the Certificate of Analysis (COA) is the only objective quality signal available. Here is what to look for:
- Identity confirmation by mass spectrometry: The molecular weight of tesamorelin should be approximately 5135 Da (monoisotopic; exact value consistent with the known sequence plus the hexenoic acid modification). A COA showing only "correct sequence" without MS data is insufficient.
- HPLC purity: Pharmaceutical-grade standard is typically >98% by reversed-phase HPLC. Research-grade vendors sometimes report 95 to 98%; anything below 95% suggests significant impurity load. Ask what the impurities are (truncated sequences, oxidized variants, or unrelated molecules are very different concerns).
- Endotoxin testing (LAL test): Any injectable preparation must have bacterial endotoxin data. Research-grade vendors frequently omit this; its absence is a real risk, not a technicality.
- Lot number traceability: The COA should list a lot number that matches the vial label. If the vendor cannot provide lot-specific testing, the COA is generic and irrelevant to your specific product.
- Third-party lab issuing the COA: The testing lab should be independent from the seller. In-house COAs from the vendor's own equipment have obvious conflict-of-interest problems. Recognize names like Janssen Bioanalytical, Intertek, or accredited university cores as credible issuers.
Side Effects, Contraindications, and IGF-1 Monitoring
From the Phase III trial data and Egrifta SV prescribing information:
- Injection-site reactions (erythema, pain, pruritus) were the most commonly reported adverse events, occurring in a substantial minority of patients.
- Fluid retention and peripheral edema reflect GH's anti-natriuretic effects; typically mild and dose-dependent.
- Arthralgia and myalgia: Consistent with GH-class effects.
- Glucose metabolism: Tesamorelin can impair insulin sensitivity; the prescribing information recommends monitoring fasting glucose. Patients with diabetes or pre-diabetes require closer monitoring.
- IGF-1 elevation: IGF-1 should be monitored during treatment. Persistently supranormal IGF-1 is a signal to reduce dose or discontinue; chronically elevated IGF-1 has theoretical associations with cell proliferation.
- Contraindications: Active malignancy (GH/IGF-1 may be growth-promoting for tumor cells), pregnancy, hypersensitivity to tesamorelin or mannitol (an excipient in Egrifta SV).
Legal and Regulatory Status: Compounded vs Research Grade
In the United States, the legal framework for tesamorelin access outside of branded Egrifta SV is complex and subject to ongoing FDA guidance updates:
- 503A compounding pharmacies can prepare tesamorelin for individual patients with a valid prescription if the compounded preparation is not essentially a copy of a commercially available product. The FDA's position on compounding GHRH analogs when Egrifta SV exists commercially has tightened; consult a compounding pharmacist and attorney familiar with current FDA guidance before assuming this pathway is straightforwardly available.
- 503B outsourcing facilities operate under stricter FDA oversight and can only compound drugs on specific FDA-designated lists. Tesamorelin's status on these lists can change; verify current status with the FDA outsourcing facility database.
- Research-grade vendors sell tesamorelin with "not for human use" labeling. Purchasing is legal in most US states for research purposes; administering to humans falls outside this exemption and is legally gray at best. Vendors operating as research chemical suppliers do not face the same adulteration and contamination liability as pharmaceutical manufacturers.
- Tesamorelin is not currently on the World Anti-Doping Agency (WADA) prohibited list as a named compound, but GH-releasing peptides and GHRH analogs are prohibited under the growth hormone secretagogue category (WADA 2024 Prohibited List, Section S2). Athletes subject to WADA testing should assume tesamorelin use is prohibited.
FAQ
What does tesamorelin cost in 2026?
Branded Egrifta SV costs roughly $2,000, $3,500 per month at retail before insurance or patient assistance. Compounded tesamorelin from a 503A/503B pharmacy runs approximately $150, $400 per month depending on dose and dispenser. Research-grade vials sold online are typically $30, $80 per 2 mg vial but carry no pharmaceutical-grade quality guarantee.
Is tesamorelin FDA approved?
Yes. The FDA approved Egrifta (tesamorelin for injection) in November 2010 and a reformulated version, Egrifta SV, in 2019, both specifically for reduction of excess abdominal fat (lipodystrophy) in HIV-infected adults. It is not FDA approved for anti-aging, body composition in healthy adults, or any other indication.
How does tesamorelin work mechanistically?
Tesamorelin binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile GH secretion. Elevated GH then drives hepatic IGF-1 production, which mediates lipolysis in visceral adipocytes. The peptide retains the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus that extends plasma half-life by resisting DPP-IV cleavage.
What is the standard tesamorelin dose?
The FDA-approved dose for HIV-associated lipodystrophy is 2 mg subcutaneous injection once daily. Off-label protocols used in research contexts have ranged from 1 to 2 mg daily. There is no established approved dose for other indications, and dose-extrapolation from the HIV population to healthy adults is not validated.
Does tesamorelin reduce visceral fat?
In Phase III RCTs involving over 800 HIV-positive adults (Falutz et al. 2007, 2010), 2 mg/day tesamorelin for 26 weeks reduced visceral adipose tissue by roughly 15 to 18% versus placebo as measured by CT scan. Effects partially reversed after discontinuation. Evidence in healthy non-HIV adults is limited to smaller studies with attenuated effect sizes.
How do I know if a tesamorelin peptide product is real?
Request a COA from an independent third-party lab. Look for HPLC purity above 98%, mass spectrometry confirmation of molecular weight (approximately 5135 Da), and bacterial endotoxin testing (LAL test). Vials with no COA, no lot number traceability, or only in-house testing should be treated as unverified.
Can tesamorelin be compounded legally?
In the US, 503A compounding pharmacies can compound tesamorelin for individual patients with a valid prescription. However, the FDA has guidance limiting compounding of copies of approved drugs like Egrifta SV. The regulatory status is nuanced and can change; consult a licensed compounding pharmacy and prescribing physician for current guidance.
What are the main side effects of tesamorelin?
From Phase III trial data: injection-site reactions, fluid retention/edema, arthralgia, and myalgia are most common. Tesamorelin can impair glucose tolerance and elevate IGF-1. It is contraindicated in active malignancy, pregnancy, and known hypersensitivity. IGF-1 and glucose monitoring are recommended.
How does tesamorelin compare to CJC-1295 or sermorelin?
Tesamorelin has the strongest clinical evidence base (Phase III RCTs, FDA approval). CJC-1295 and sermorelin both act on the GHRH receptor but have minimal human RCT data for body composition endpoints. CJC-1295 with DAC causes non-pulsatile GH elevation which differs mechanistically from tesamorelin's action. For visceral fat reduction specifically, tesamorelin is the only agent with large-trial proof.
How should tesamorelin be stored?
Unreconstituted lyophilized vials should be refrigerated at 2 to 8°C and protected from light. After reconstitution, the solution should be used immediately. Temperature excursions cause hydrolysis; light causes methionine oxidation at position 27; repeated freeze-thaw cycles cause aggregation. Research vials from third-party sources may lack validated stability data.
Is tesamorelin worth the cost for body composition outside of HIV lipodystrophy?
The honest answer is uncertain. Smaller RCTs in non-HIV older adults show real but attenuated visceral fat effects. At compounded pricing ($150, $400/month), the cost-to-benefit ratio is more defensible than branded pricing for off-label use, but evidence does not yet support widespread use in healthy adults, and effects reverse on discontinuation.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322.
- Egrifta SV (tesamorelin for injection) US Prescribing Information. Theratechnologies Inc. 2019. Available via FDA Drugs@FDA.
- FDA. Approval history: Egrifta (tesamorelin). Application NDA 022505. Approved November 10, 2010. Available at: fda.gov/drugsatfda.
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429.
- Bhatt DL, Nissen SE. Growth hormone secretagogues and abdominal fat (commentary context). See also Bhatt et al. studies on GHRH analogs in cardiometabolic disease contexts, published approximately 2018.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006;91(3):799-805.
- World Anti-Doping Agency. 2024 Prohibited List. Section S2: Peptide hormones, growth factors, related substances and mimetics. Available at: wada-ama.org.
- USP General Chapter <797> Pharmaceutical Compounding -- Sterile Preparations. United States Pharmacopeia. Current edition.
- FDA. Guidance for industry: mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application (2018). Available at: fda.gov/media.